Form 4: Lifecore Biomedical Director Acquires 30,000 Shares of Common Stock

Director Craig A. Barbarosh acquired 30,000 shares of Lifecore Biomedical, Inc. common stock through restricted stock units.

Summary

• On July 8, 2024, Craig A. Barbarosh, a director of Lifecore Biomedical, Inc., acquired 30,000 shares of common stock.
• The acquisition was made through restricted stock units (RSUs).
• These RSUs convert into common stock on a 1-for-1 basis.
• The RSUs vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.
• Following the transaction, Barbarosh indirectly owns 88,073 shares in trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director. While insider buying can be seen as positive, it's not overwhelmingly so without additional context.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units is contingent upon the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates